275 related articles for article (PubMed ID: 35483923)
1.
Ahn JS; Kim HJ
Blood Res; 2022 Apr; 57(S1):32-36. PubMed ID: 35483923
[TBL] [Abstract][Full Text] [Related]
2. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J; Song Y; Liu D
Biomark Res; 2019; 7():19. PubMed ID: 31528345
[TBL] [Abstract][Full Text] [Related]
3. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia.
Short NJ; Kantarjian H; Ravandi F; Daver N
Ther Adv Hematol; 2019; 10():2040620719827310. PubMed ID: 30800259
[TBL] [Abstract][Full Text] [Related]
4. FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile.
Garciaz S; Hospital MA
Onco Targets Ther; 2023; 16():31-45. PubMed ID: 36698434
[TBL] [Abstract][Full Text] [Related]
5. A Review of FLT3 Kinase Inhibitors in AML.
Negotei C; Colita A; Mitu I; Lupu AR; Lapadat ME; Popovici CE; Crainicu M; Stanca O; Berbec NM
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892567
[TBL] [Abstract][Full Text] [Related]
6. French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study.
Garnham A; Bruon F; Berthon C; Lebon D; Parimi M; Polya R; Makhloufi KM; Dramard-Goasdoue MH
Oncol Ther; 2023 Sep; 11(3):375-389. PubMed ID: 37578642
[TBL] [Abstract][Full Text] [Related]
7. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Tzogani K; Røshol H; Olsen HH; Aas IB; Dalhus ML; Håkonsen GD; Nilssen LS; Lindberg V; Økvist M; Bolstad B; Rogovska I; Karpova N; Enzmann H; Gisselbrecht C; Pignatti F
Oncologist; 2020 Jul; 25(7):e1070-e1076. PubMed ID: 32154636
[TBL] [Abstract][Full Text] [Related]
8. A review of FLT3 inhibitors in acute myeloid leukemia.
Zhao JC; Agarwal S; Ahmad H; Amin K; Bewersdorf JP; Zeidan AM
Blood Rev; 2022 Mar; 52():100905. PubMed ID: 34774343
[TBL] [Abstract][Full Text] [Related]
9. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of gilteritinib in combination with chemotherapy in preclinical models of
Ueno Y; Mori M; Kamiyama Y; Saito R; Kaneko N; Isshiki E; Kuromitsu S; Takeuchi M
Oncotarget; 2019 Apr; 10(26):2530-2545. PubMed ID: 31069015
[TBL] [Abstract][Full Text] [Related]
11. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
McMahon CM; Perl AE
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
[No Abstract] [Full Text] [Related]
12. FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Novatcheva ED; Anouty Y; Saunders I; Mangan JK; Goodman AM
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e161-e184. PubMed ID: 34649791
[TBL] [Abstract][Full Text] [Related]
13. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
Daver N; Venugopal S; Ravandi F
Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
[TBL] [Abstract][Full Text] [Related]
14. "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.
Knight TE; Edwards H; Meshinchi S; Taub JW; Ge Y
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884458
[TBL] [Abstract][Full Text] [Related]
15. Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat
Molica M; Perrone S; Rossi M
J Clin Med; 2023 May; 12(11):. PubMed ID: 37297842
[TBL] [Abstract][Full Text] [Related]
16. Target Therapy for Extramedullary Relapse of
Duminuco A; Maugeri C; Parisi M; Mauro E; Fiumara PF; Randazzo V; Salemi D; Agueli C; Palumbo GA; Santoro A; Di Raimondo F; Vetro C
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565314
[TBL] [Abstract][Full Text] [Related]
17. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
18. Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of
Kondo T; Onozawa M; Fujisawa S; Harada S; Ogasawara R; Izumiyama K; Saito M; Morioka M; Mori A; Teshima T
Hematology; 2021 Dec; 26(1):256-260. PubMed ID: 33631087
[No Abstract] [Full Text] [Related]
19. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of FLT3 inhibitors in acute myeloid leukemia.
Sutamtewagul G; Vigil CE
Onco Targets Ther; 2018; 11():7041-7052. PubMed ID: 30410361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]